Literature DB >> 29734147

Large Renal Corpuscle: Clinical Significance of Evaluation of the Largest Renal Corpuscle in Kidney Biopsy Specimens.

Hiroshi Kataoka, Toshio Mochizuki, Kosaku Nitta.   

Abstract

Renal prognostic factors of chronic kidney disease are important concerns for patients. Kidney biopsy can be used to evaluate not only the activity of the original disease but also various risk factors related to the lifestyle of patients. Considering that lifestyle-related factors, including obesity and metabolic syndrome, are crucial prognostic risk factors of kidney disease progression and all-cause mortality, evaluation of lifestyle-related prognostic factors in kidney biopsy of all kidney diseases is important. Renal corpuscle size (glomerular size) is an easily measured parameter and potentially acts as a predictor of long-term renal function. Large renal corpuscle found on kidney biopsy is a classic and simple indicator, and has merit owing to its quantitative nature, but it has yet to be used to its full potential in clinical settings. Large renal corpuscle is an index that includes not only the activity of the original disease but also the damage of various metabolic risk states as represented by obesity, diabetes, and metabolic syndrome. Large renal corpuscles could be used to guide therapy. In this review, after identifying the pitfalls regarding the assessment of mean values in medical research, we propose that measurement of the maximum renal corpuscle profile (glomerular profile) in renal biopsies would provide valuable insights into the diagnosis, prognosis, and management of kidney diseases.
© 2018 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2018        PMID: 29734147     DOI: 10.1159/000486931

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  5 in total

1.  Impact of visceral fat area in patients with chronic kidney disease.

Authors:  Shun Manabe; Hiroshi Kataoka; Toshio Mochizuki; Kazuhiro Iwadoh; Yusuke Ushio; Keiko Kawachi; Kentaro Watanabe; Saki Watanabe; Taro Akihisa; Shiho Makabe; Masayo Sato; Naomi Iwasa; Rie Yoshida; Yukako Sawara; Norio Hanafusa; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2021-02-17       Impact factor: 2.801

2.  Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.

Authors:  Hiroshi Kataoka; Toshio Mochizuki; Taro Akihisa; Kentaro Kawasoe; Keiko Kawachi; Shiho Makabe; Anri Sawada; Shun Manabe; Masayo Sato; Nobuyuki Amemiya; Michihiro Mitobe; Takafumi Akanuma; Yasuko Ito; Takahiro Inoue; Tomo Suzuki; Katsuomi Matsui; Takahito Moriyama; Shigeru Horita; Mamiko Ohara; Kazuho Honda; Kosaku Nitta
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

3.  Maximum Glomerular Diameter and Oxford MEST-C Score in IgA Nephropathy: The Significance of Time-Series Changes in Pseudo-R2 Values in Relation to Renal Outcomes.

Authors:  Hiroshi Kataoka; Takahito Moriyama; Shun Manabe; Keiko Kawachi; Yusuke Ushio; Saki Watanabe; Taro Akihisa; Shiho Makabe; Masayo Sato; Naomi Iwasa; Yukako Sawara; Mamiko Ohara; Sekiko Taneda; Keiko Uchida; Kazuho Honda; Toshio Mochizuki; Ken Tsuchiya; Kosaku Nitta
Journal:  J Clin Med       Date:  2019-12-02       Impact factor: 4.241

4.  Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.

Authors:  Hiroshi Kataoka; Toshio Mochizuki; Mamiko Ohara; Yuki Tsuruta; Naomi Iwasa; Rie Yoshida; Ken Tsuchiya; Kosaku Nitta; Kenjiro Kimura; Tatsuo Hosoya
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.996

5.  Visceral to subcutaneous fat ratio as an indicator of a ≥30% eGFR decline in chronic kidney disease.

Authors:  Hiroshi Kataoka; Toshio Mochizuki; Kazuhiro Iwadoh; Yusuke Ushio; Keiko Kawachi; Saki Watanabe; Kentaro Watanabe; Taro Akihisa; Shiho Makabe; Shun Manabe; Masayo Sato; Naomi Iwasa; Rie Yoshida; Yukako Sawara; Norio Hanafusa; Ken Tsuchiya; Kosaku Nitta
Journal:  PLoS One       Date:  2020-11-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.